These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1180 related articles for article (PubMed ID: 20399324)

  • 21. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
    Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
    Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
    Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
    Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Surveillance of patients with Barrett's esophagus].
    Endlicher E; Knüchel R; Messmann H
    Z Gastroenterol; 2001 Aug; 39(8):593-600. PubMed ID: 11558064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma.
    Grant KS; DeMeester SR; Kreger V; Oh D; Hagen JA; Chandrasoma P; DeMeester TR
    J Thorac Cardiovasc Surg; 2013 Jul; 146(1):31-7. PubMed ID: 23312980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
    Lim CH; Treanor D; Dixon MF; Axon AT
    Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
    Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of endoscopy surveillance for Barrett's oesophagus.
    Bright T; Schloithe A; Bull JA; Fraser RJ; Bampton P; Watson DI
    ANZ J Surg; 2009 Nov; 79(11):812-6. PubMed ID: 20078532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A surveillance programme for Barrett's oesophagus in a UK general hospital.
    Olithselvan A; Gorard DA; McIntyre AS
    Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.
    Bytzer P; Christensen PB; Damkier P; Vinding K; Seersholm N
    Am J Gastroenterol; 1999 Jan; 94(1):86-91. PubMed ID: 9934736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.
    Weston AP; Badr AS; Topalovski M; Cherian R; Dixon A; Hassanein RS
    Am J Gastroenterol; 2000 Feb; 95(2):387-94. PubMed ID: 10685740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
    Quera R; O'Sullivan K; Quigley EM
    Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia.
    Reid BJ; Blount PL; Feng Z; Levine DS
    Am J Gastroenterol; 2000 Nov; 95(11):3089-96. PubMed ID: 11095322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.
    Cameron AJ; Carpenter HA
    Am J Gastroenterol; 1997 Apr; 92(4):586-91. PubMed ID: 9128304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
    O'Connor JB; Falk GW; Richter JE
    Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Barrett's esophagus free of dysplasia.
    DeMeester SR
    Semin Thorac Cardiovasc Surg; 1997 Jul; 9(3):279-84. PubMed ID: 9263346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer.
    Fountoulakis A; Zafirellis KD; Dolan K; Dexter SP; Martin IG; Sue-Ling HM
    Br J Surg; 2004 Aug; 91(8):997-1003. PubMed ID: 15286961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.